Having amassed a significant body of clinical evidence in the field of oncology, Taiho Pharmaceutical has contributed to the establishment of better treatment methods for years now as Japan’s pioneer in developing oral anticancer agents. Since the start of the new millennium, Taiho Pharmaceutical has made every effort to increase its global reach, seeking to bring smiles to the faces of more patients around the world. The company is pursuing global R&D while building its own sales structure in the U.S. and expanding its sales network in other countries.
Taiho has appointed a Global Chief Corporate Officer (GCCO) and a Global Chief Medical Officer (GCMO) tasked with taking a bird’s-eye view of national, regional, and functional differences to optimize global operations overall.
At the Tokyo head office, the department under the GCCO optimizes corporate functions for the entire Taiho Group in and outside Japan. The department under the GCMO plans portfolio strategy from a global perspective, aiming for overall optimization.
In 2002, Taiho Pharmaceutical established Taiho Pharma U.S.A., Inc. (now Taiho Oncology, Inc.) in Princeton, New Jersey in the U.S. Its select team of professionals works together with medical professionals and organizations in the U.S. and Europe, while cooperating with Taiho Pharmaceutical staff in Japan, to advance the global development of new drugs that can contribute to the treatment of cancer.
LONSURF became Taiho Pharmaceutical’s first product in North America when the U.S. FDA approved it in 2015. Taiho Oncology, Inc. has been marketing the drug since that time.
In 2016, the corporate venture capital company, Taiho Ventures, LLC, was established in California in the U.S. for the purpose of biotechnology investment.
The new company invests in promising biotechnology ventures around the world that are engaged in innovative new drug R&D as well as cutting-edge drug-enabling platform technologies, mainly in the oncology field. It also takes advantage of the resources Taiho Pharmaceutical has cultivated as a pioneer of oral anticancer drugs on behalf of its portfolio companies.
Through Taiho Ventures, LLC, Taiho Pharmaceutical searches for partnering opportunities with promising venture companies in order to enhance its development pipeline and acquire innovative drug discovery technologies.
In 2016, Taiho Pharma Canada, Inc. was established as a new harmaceutical business base in that country. In 2018, Health Canada, the Canadian health authority, approved LONSURF. Taiho Pharma Canada, Inc. has been marketing the drug since that time.
In 2009, Taiho Pharmaceutical established Taiho Pharma Europe, Ltd. to serve as its drug development center in Europe. Working closely with the professional R&D teams in Japan and the U.S., Taiho Pharma Europe, Ltd. provides direct management of research and development programs and regulatory affairs support toward obtaining marketing approval of anticancer drugs in the European markets.
In Europe, Teysuno (called TS-1 in Japan), which was approved in 2011 as a treatment for advanced gastric cancer, is sold through Nordic Group BV, the company’s Netherlands-based partner. In 2015, Taiho Pharmaceutical entered into a license agreement with Servier (France) for co-development and commercialization of LONSURF, a treatment for metastatic colorectal cancer, in Europe and other regions (excluding North America and Asia). After receiving approval for the drug from the European Commission in 2016, sales have been expanded in countries there through Servier.
In 2011, Taiho Pharmaceutical established Taiho Pharma Singapore Pte. Ltd. as a development and marketing base in Southeast Asia. The new company is marketing the anticancer agents TS-1 (known as TS-ONE locally), LONSURF, UFT and Futraful either independently or through business partners.
Sticking with its philosophy, “by local, for local,” Taiho Pharma Singapore Pte. Ltd. covers a wide range of jobs such as regulatory affairs, medical affairs and sales of anticancer drugs as a hub for Taiho’s oncology business in Southeast Asia in close touch with local medical oncologists and the other medical professionals in cancer care.
In 2008, Taiho Pharmaceutical established the Chinese subsidiary, Taiho Pharmaceutical of Beijing Co., Ltd., to serve the development and marketing function in China. The new company obtains approval from authorities in China on anticancer agents researched and developed by Taiho Pharmaceutical and provides product information to Chinese oncologists.
In 2009, the company launched TS-1 as its first product and is currently developing its business.
In July 2016, Taiho Pharmaceutical established Global One Academy as the Taiho Group’s corporate university to develop global leaders who can demonstrate change leadership and solve management issues. The academy seeks to develop the next generation of company leadership. Participants go through a rigorous selection process to be admitted. They learn the basic skills essential for the leaders of the future, including rational approaches to task-setting and problem-solving, communication skills, and more. The participants are already implementing these skills in their everyday work.
Taiho Pharmaceutical created the TAIHO ONCOLOGY brand to leverage its Japanese reputation worldwide, seeking to increase its global market recognition as a leader in the field of oncology. The company is promoting the brand at academic conferences, pursuing open innovation based on cooperation with farsighted medical professionals and researchers. The TAIHO ONCOLOGY brand stands for the determination to create cancer treatments that will more quickly and more definitely become global standards, for the benefit of patients worldwide.